Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia
| Autor: | Leif Lohrbauer, Donald B. Hunninghake, Peter B. Jones, Stephanie Kafonek, William Insull, Robert H. Knopp, Michael H. Davidson |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male medicine.medical_specialty Statin Apolipoprotein B medicine.drug_class Pyridines Atorvastatin Hypercholesterolemia Administration Oral Gastroenterology Drug Administration Schedule chemistry.chemical_compound Double-Blind Method Internal medicine medicine Humans Pyrroles Prospective Studies Adverse effect National Cholesterol Education Program Triglycerides Aged Apolipoproteins B Aged 80 and over biology Cholesterol business.industry Anticholesteremic Agents Cholesterol HDL Cerivastatin Cholesterol LDL Middle Aged United States Endocrinology Treatment Outcome chemistry Heptanoic Acids biology.protein Cardiology lipids (amino acids peptides and proteins) Female Cardiology and Cardiovascular Medicine business medicine.drug Lipoprotein |
| Zdroj: | The American journal of cardiology. 88(6) |
| ISSN: | 0002-9149 |
| Popis: | This 6-week Prospective, Randomized, Open-label Blinded End point (PROBE) study conducted at 12 sites in the United States compared the efficacy and safety of atorvastatin with cerivastatin. In all, 215 hypercholesterolemic patients (low-density lipoprotein [LDL] cholesterol ≥160 mg/dl [4.14 mmol/L]; triglycerides ≤400 mg/dl [4.52 mmol/L]) were randomized to receive either atorvastatin 10 mg once daily (n = 108) or cerivastatin 0.3 mg once daily (n = 107). Efficacy was assessed by measuring changes from baseline in LDL cholesterol, total cholesterol, high-density lipoprotein cholesterol, apolipoprotein B, and triglycerides. Atorvastatin produced significantly greater (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect